XML 49 R37.htm IDEA: XBRL DOCUMENT v3.25.3

Collaborative Research and Development Agreements - Schedule of Milestone Achieved (Details) - USD ($)		3 Months Ended												9 Months Ended
	Jan. 31, 2025	Sep. 30, 2025	Dec. 31, 2024	Sep. 30, 2024	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Mar. 31, 2020	Jun. 30, 2019	Sep. 30, 2018	Jun. 30, 2017	Mar. 31, 2016	Jun. 30, 2015	Sep. 30, 2025	Sep. 30, 2024	Oct. 31, 2021
Disaggregation of Revenue [Line Items]
Collaboration revenue		$ 76,320,000		$ 30,017,000										$ 126,354,000	$ 48,167,000
Milestone revenue recognition														Cash is generally received within 30 days of milestone achievement
GSK | PD-1 (Jemperli/Dostarlimab) | Initiated in vivo toxicology studies using good laboratory practices (GLPs)
Disaggregation of Revenue [Line Items]
Collaboration revenue													$ 1,000,000.0
GSK | PD-1 (Jemperli/Dostarlimab) | IND clearance from the FDA
Disaggregation of Revenue [Line Items]
Collaboration revenue												$ 4,000,000.0
GSK | PD-1 (Jemperli/Dostarlimab) | Phase 2 clinical trial initiation
Disaggregation of Revenue [Line Items]
Collaboration revenue											$ 3,000,000.0
GSK | PD-1 (Jemperli/Dostarlimab) | Phase 3 clinical trial initiation - first indication
Disaggregation of Revenue [Line Items]
Collaboration revenue										$ 5,000,000.0
GSK | PD-1 (Jemperli/Dostarlimab) | Phase 3 clinical trial initiation - second indication
Disaggregation of Revenue [Line Items]
Collaboration revenue									$ 5,000,000.0
GSK | PD-1 (Jemperli/Dostarlimab) | Filing of the first BLA - first indication
Disaggregation of Revenue [Line Items]
Collaboration revenue								$ 10,000,000.0
GSK | PD-1 (Jemperli/Dostarlimab) | Filing of the first MAA - first indication
Disaggregation of Revenue [Line Items]
Collaboration revenue								$ 5,000,000.0
GSK | PD-1 (Jemperli/Dostarlimab) | Filing of the first BLA - second indication
Disaggregation of Revenue [Line Items]
Collaboration revenue							$ 10,000,000.0
GSK | PD-1 (Jemperli/Dostarlimab) | First BLA approval - first indication
Disaggregation of Revenue [Line Items]
Collaboration revenue						$ 20,000,000.0
GSK | PD-1 (Jemperli/Dostarlimab) | First MAA approval - first indication
Disaggregation of Revenue [Line Items]
Collaboration revenue						$ 10,000,000.0
GSK | PD-1 (Jemperli/Dostarlimab) | First BLA approval - second indication
Disaggregation of Revenue [Line Items]
Collaboration revenue					$ 20,000,000.0
GSK | PD-1 (Jemperli/Dostarlimab) | Filing of the first MAA - second indication
Disaggregation of Revenue [Line Items]
Milestones that may be recognized in the future														$ 5,000,000.0
GSK | PD-1 (Jemperli/Dostarlimab) | First MAA approval - second indication
Disaggregation of Revenue [Line Items]
Milestones that may be recognized in the future														10,000,000.0
GSK | PD-1 (Jemperli/Dostarlimab) | First commercial sales milestone
Disaggregation of Revenue [Line Items]
Collaboration revenue				$ 15,000,000											$ 15,000,000
GSK | PD-1 (Jemperli/Dostarlimab) | Second commercial sales milestone
Disaggregation of Revenue [Line Items]
Collaboration revenue			$ 25,000,000.0
GSK | PD-1 (Jemperli/Dostarlimab) | Third commercial sales milestone
Disaggregation of Revenue [Line Items]
Collaboration revenue		$ 50,000,000.0												50,000,000
GSK | PD-1 (Jemperli/Dostarlimab) | Fourth commercial sales milestone
Disaggregation of Revenue [Line Items]
Milestones that may be recognized in the future														75,000,000.0
GSK | PD-1 (Jemperli/Dostarlimab) | Milestones recognized through September 30, 2025
Disaggregation of Revenue [Line Items]
Collaboration revenue														183,000,000.0
GSK | PD-1 (Jemperli/Dostarlimab) | Milestones that may be recognized in the future
Disaggregation of Revenue [Line Items]
Milestones that may be recognized in the future														90,000,000.0
Sagard | JEMPERLI Royalty Monetization Agreement
Disaggregation of Revenue [Line Items]
Rights retained																$ 75,000,000
Royalties agreement, maximum annual royalty payout capacity																$ 1,000,000,000
Vanda | Milestones recognized through September 30, 2025
Disaggregation of Revenue [Line Items]
Collaboration revenue														0
Milestones that may be recognized in the future														35,000,000.0
Vanda | FDA regulatory approval for marketing of first licensed product in the USA for the treatment of active flares in GPP
Disaggregation of Revenue [Line Items]
Milestones that may be recognized in the future														5,000,000.0
Vanda | Regulatory approval for marketing of the first licensed product in the EU
Disaggregation of Revenue [Line Items]
Milestones that may be recognized in the future														5,000,000.0
Vanda | Commercial sales first exceed $100.0 million
Disaggregation of Revenue [Line Items]
Milestones that may be recognized in the future														25,000,000.0
Commercial sales														$ 100,000,000.0
Vanda | Exclusive License Agreement
Disaggregation of Revenue [Line Items]
Royalty percent on net sales (as a percent)	10.00%

X

- Definition

Advance Future Royalties, Annual Sales Threshold

+ References

No definition available.

+ Details

Name:	anab_AdvanceFutureRoyaltiesAnnualSalesThreshold
Namespace Prefix:	anab_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Advance Future Royalties, Retained Rights After Annual Sales Threshold Exceeded

+ References

No definition available.

+ Details

Name:	anab_AdvanceFutureRoyaltiesRetainedRightsAfterAnnualSalesThresholdExceeded
Namespace Prefix:	anab_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Net Sales Royalty, Percent

+ References

No definition available.

+ Details

Name:	anab_NetSalesRoyaltyPercent
Namespace Prefix:	anab_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Net Sales Royalty Threshold

+ References

No definition available.

+ Details

Name:	anab_NetSalesRoyaltyThreshold
Namespace Prefix:	anab_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Revenue Recognition, Milestone Method, Contingent

+ References

No definition available.

+ Details

Name:	anab_RevenueRecognitionMilestoneMethodContingent
Namespace Prefix:	anab_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Description of effect, from relationship that timing of satisfaction of performance obligation has on timing of payment, on right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time and on obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-9

+ Details

Name:	us-gaap_ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

+ Details

Name:	us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	srt_CounterpartyNameAxis=anab_GlaxoSmithKlineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=anab_AnaptysBioGeneratedAntiPD1JemperliDostarlimabMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_InVivoToxicologyStudiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_ClearanceOfInvestigationalNewDrugFromFDAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_Phase2ClinicalTrialInitiationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_Phase3ClinicalTrialInitiationFirstIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_Phase3ClinicalTrialInitiationSecondIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_FilingOfBiologicsLicenseApplicationFirstIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_FilingOfMMAFirstIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_FilingOfBiologicsLicenseApplicationSecondIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_FirstBiologicsLicenseApplicationApprovalDMMRECMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_FirstMarketingAuthorizationApplicationApprovalFirstIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_FirstBiologicsLicenseApplicationApprovalSecondIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_FilingOfMMASecondIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_FirstMarketingAuthorizationApplicationApprovalSecondIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_FirstCommercialSalesMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_SecondCommercialSalesMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_ThirdCommercialSalesMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_FourthCommercialSalesMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_CumulativeMilestonesRecognizedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_MilestonesYetToBeRecognizedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=anab_SagardHealthcareRoyaltyPartnersLPMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_JEMPERLIRoyaltyMonetizationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=anab_VandaPharmaceuticalsInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_FDARegulatoryApprovalForMarketingOfFirstLicensedProductInTheUSAForTheTreatmentOfActiveFlaresInGPPMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_RegulatoryApprovalForMarketingOfTheFirstLicensedProductInTheEUMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_CommercialSalesMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_ExclusiveLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: